General research

The easiest way to keep up with type 1 diabetes research is by signing up for the weekly What's New research update on the Children with Diabetes website. You can receive a weekly e-mail newsletter with a number of links. These newsletters include something for everyone, everything from a list of kids looking for penpals, to FAQs and online discussions for parents, to late-breaking clinical and research developments. The entire CWD site is very well edited and up-to-date, and it's our most highly recommended site for children with diabetes, their families, and their health-care providers.

One nice site for everone is TypeOneNation, the Juvenile Diabetes Research Foundation's online forum for the type 1 diabetes community, including groups for teens and preteens, for parents, for friends, and for the newly diagnosed.

Other recommended e-subscription sites—all free!—which provide current diabetes (type 1 and type 2) research information are listed below.

e-Newsletters

• Children with Diabetes: What's New this Week
• Juvenile Diabetes Research Foundation Canada: T1D Insider
• Juvenile Diabetes Research Foundation USA: T1D news and events sign-up
• Canadian Diabetes Association: Diabetes Current
• American Diabetes Association: E-newsletter sign-up
• International Diabetes Federation/World Diabetes Congress: News
• David Mendosa's Diabetes Developments Blog
• Diabetes in Control: weekly newsletter
• diaTribe

Genetics, incidence, demographics & complications studies

• Study to Examine Rates of Childhood Diabetes (SEARCH)
• The Environmental Determinants of Diabetes in the Young (TEDDY)
• TEENDIAB Study
• Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT)
• Environmental Determinants of Islet Autoimmunity (ENDIA)

Prevention & treatment studies

• Type 1 Diabetes TrialNet
  • Pathway to Prevention: Natural History Study of the Development of Type 1 Diabetes
  • CTLA4-Ig (Abatacept) for Prevention of Type 1 Diabetes in Relatives At-Risk
  • Anti-CD3 mAb (Teplizumab) for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
• Immune Tolerance Network
  • Study of Thymoglobulin to Arrest Type 1 Diabetes (START)
  • Preserving Beta-Cell Function with Tocilizumab in New-Onset Type 1 Diabetes (EXTEND)
  • Cytokine Production in Children with Pre-Clinical and Clinical Type 1 Insulin Dependent Diabetes Mellitus (ABBA)
  • T1D Extended Study (T1DES)
• INIT II Trial (intranasal insulin)
• Trial to Reduce IDDM in the Genetically At-Risk (TRIGR)
• Diabetes Research in Children Network (DirecNet)
• Diabetes Attitudes, Wishes & Needs (DAWN2™)

Vaccines

• Diamyd Medical: Diamyd™ vaccine studies
• Tolerian: TOL-3021 vaccine
• Parvus Therapeutics: NavacimTD vaccine
• MultiPepT1De study
• Selecta Biosciences: t₂SVP™ vaccine
• BCG vaccine

Stem-cell, engineered-cell, gene-therapy & islet neogenesis research

• ViaCyte: VC-01 (PEC-01™ cell therapy and Encaptra™ drug-delivery system)
• enGene: EG-02 technology with intestinal K cells
• Transition Therapeutics: Islet Neogenesis Therapy (E1-INT™)
• Theracyte: regulated insulin-producing cell line
• Exsulin: Exsulin (INGAP)
• Cure DM: Pancreate™

Artificial pancreas

• JDRF's Artificial Pancreas Project
• Bionic Pancreas
• Institut de recherches cliniques de Montréal (IRCM) artificial pancreas
• βetα βionics: iLet™ bionic pancreas
• University of Virginia artificial pancreas
• University of Cambridge artificial pancreas project

Insulin analogs

• Rapid-acting analogs:
  • Halozyme Therapeutics: ENHANZE™ (rHuPH20) technology to accelerate insulin action
  • Novo Nordisk: NN-1218 (FIAsp, faster-acting insulin aspart)
  • Eli Lilly: faster-acting insulin lispro
  • Adocia and Eli Lilly: BioChaperone® Lispro
• Basal insulins:
  • Novo Nordisk: NN-1436 (weekly basal insulin)
  • Merck: MK-1293 (biosimilar insulin glargine)
• Smart (glucose-dependent) insulins/nanotechnology:
  • Merck: SmartInsulin™
  • Sensulin™: Agglomerated Vesicle Technology
  • Injectable Nano-Network for Glucose-Mediated Insulin Delivery

Inhaled insulins

• MannKind: AFREZZA™

Oral insulins

• Generex Biotechnology: Oral-lyn™
• Biocon: insulin tregopil (IN-105)
• Diabetology: Capsulin™
• Novo Nordisk: NN-1953 (oral basal insulin analog)
• Oramed Pharmaceuticals: ORMD-0801

Transdermal insulins

• University of North Carolina: smart insulin patch

Novel glucagon preparations

• Xeris Pharmaceuticals: G-Pump™ (stable liquid glucagon for pumps), G-Pen™
• LATITUDE Pharmaceuticals: Nano-G (stable liquid glucagon)
• Locemia/Eli Lilly: intranasal glucagon

Novel drugs for diabetes

• Merck Research Laboratories: demethylasterriquinone B1 (L-783,281)
• MacroGenics: teplizumab [hOKT3γ1(Ala-Ala)]
• Glaxo Smith Kline: otelixizumab (TRX4, ChAglyCD3)

Non- & minimally invasive glucose testing

• A. Menarini Diagnostics: GlucoDay® S Continuous Glucose Monitoring
• Echo Therapeutics: non-invasive blood glucose monitoring
• Google X Labs: smart contact lens project
• Senseonics: Eversense™ Continuous Glucose Monitoring System
• Dexcom: G5 Mobile Continuous Glucose Monitoring System
• Abbott Diabetes Care: FreeStyle® Libre™ flash glucose monitoring system
• OrSense: NBM-200G non-invasive blood glucose meter
• PKvitality: K'Trak Glucose wearable tracker
• Luminor Medical Technologies: SCOUT DS® diabetes screen